ArticleCommunications medicine2025
Liquid biopsy diagnostics for non-small cell lung cancer via elucidation of tRNA signatures.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next-Generation Approaches.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Rewriting Tumor Entry Rules: Microfluidic Polyplexes and Tumor-Penetrating Strategies-A Literature Review.Pharmaceutics · 2026Review
- Integrative multi-omics and experimental analyses implicate PTK2 as a lorazepam-associated biomarker and potential therapeutic target in ovarian cancer.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundLung cancer, particularly non-small cell lung cancer (NSCLC), accounts for about 85% of all lung cancer cases and remains a major global health challenge. Traditional diagnostic methods, such as chest X-rays and low-dose CT scans, have limitations, including high false-positive rates, radiation risks, and the invasiveness of tissue biopsies. This study aims to develop a non-invasive liquid biopsy approach for early NSCLC diagnosis.
methodsWe developed a machine-learning model to analyze small RNA sequencing data from 1446 tissue samples to identify a diagnostic tRNA signature. This signature was independently validated using the in-house data of 233 plasma exosome samples. Diagnostic performance was assessed using Area Under the Curve (AUC) metrics. Signature tRNAs were then evaluated across various clinical and demographic variables, with further survival analysis and functional studies to explore the molecular role of the signature tRNAs.
resultsWe identify a robust six-tRNA signature with strong diagnostic performance, achieving AUC values of 0.97 in discovery, 0.96 in hold-out validation, and 0.84 in independent validation. The signature effectively distinguishes cancerous from benign samples (AUC = 0.85) and consistently performs across clinical and demographic variables, with AUC values exceeding 0.80, particularly for early-stage lung cancer diagnosis. Additionally, three signature tRNAs demonstrate prognostic value for independent survival prediction. Functional studies suggest potential regulatory roles of specific tRNAs and their associated fragments in tumor metabolism pathways.
conclusionsThis research underscores the diagnostic power of tRNA signature for NSCLC liquid biopsy and provides epigenetic insights that enhance our understanding of oncogenic molecular pathophysiology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.